Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BBT-401, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino serve as scaffold that bind to proteins in inflammatory signaling pathways in various physio-pathological conditions. It is being investiated for inflammatory diseases such as ...
Product Name : BBT-401
Product Type : Peptide
Upfront Cash : Inapplicable
February 20, 2023
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company has confirmed both the safety and efficacy profiles of BBT-401 in active ulcerative colitis patients through the first cohort study of the Phase 2a trial.
Product Name : BBT-401
Product Type : Peptide
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Bridge Biotherapeutics Becomes BaseLaunch's First Asia Pacific Partner
Details : BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IP...
Product Name : BBT-401
Product Type : Peptide
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : BBT-401
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership